Latest Conference Articles

Thomas discusses emerging therapies, new technologies, and the reform needed to help these new developments reach the patients in need of them.

Landela’s research on an impoverished community in South Africa encourages clinicians to help similar populations get the care they need.

Nguyen spoke to the importance of being aware of heightened stress, anxiety, and depression due to myopia’s long-term treatment requirements.

Overexposure to mobile phones and similar devices can impact ocular and mental health; Roe suggests methods of managing screen time.

Lonsberry recommends alternative approaches to manage postoperative pain, balancing the need for relief against the risk of addiction and death.

Whitley speaks to the plethora of available biologics, the choice paralysis that can accompany the wide range of options, and the future of the industry.

Drs. Richman and Wartman discuss the benefits of using predictive and diagnostic AI, while cautioning about the implicit risks of overreliance on early, imperfect technology.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.

Check out insights from SDPA 2025 on eczema, alopecia, vitiligo, burnout, and JAK inhibitor workups—key tips to improve dermatology care.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

This 4-year data highlights dupilumab’s efficacy among children under the age of 12 with atopic dermatitis.

At SDPA 2025, Theodore Rosen, MD, discussed various psychological disorders, including delusions of parasitosis, excoriation disorder, dermatitis artefacta, and others.

Maria Hordinsky, MD, spoke at SDPA regarding her talk highlighting a variety of clinical pearls for spotting scarring alopecia early.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

In her SDPA interview, Maria Hordinsky, MD, spoke about her session regarding clinical pearls for clinicians seeking to spot alopecia early in patients.

At SDPA 2025, Spizuoco discussed how trichoscopic signs like black dots, yellow dots, and exclamation hairs guide treatment decisions.

This interview segment with Scherer highlights additional takeaways from his SDPA 2025 talk, covering clues for clinicians to identify different interdigital foot infections.

In this interview at SDPA, Scherer provides an overview of foot web space infections, fungal versus bacterial infections, and more.

At SDPA 2025, Cotter highlights clinical patterns in alopecia areata that may respond better, or worse, to JAK inhibition and shares his approach to systemic therapy.

Attar discusses the medication pipeline, possible AI implementation, and the importance of making patients aware of clinical trials for rare genetic diseases.

This presentation, covered at SDPA, features a discussion by Ginette Okoye, MD, who highlights diagnostic challenges among even experienced clinicians.

Lang discusses his expectations and excitement for upcoming developments in the field and encourages clinicians to work together to better treat complex patients.

At SDPA 2025, Mangin emphasized the importance of wood lamp use, JAK inhibitors, and phototherapy in managing vitiligo and preventing relapse.

Hope Cook, PA-C, speaks in this interview at SDPA about strategies for clinicians seeking to overcome burnout in their careers.